Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market - GBI Research Reports

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market - GBI Research Reports
Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
Published Feb 10, 2011
195 pages — Published Feb 10, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market, which provides insights into global antibacterial market and market forecast until 2016. The report provides an in-depth analysis of the top seven therapeutic indications for which often antibacterials are prescribed which includes tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media. The report also examines the Global antibacterial treatment usage patterns for the covered indication. In addition, the report also includes insights into the antibacterial R&D pipeline.
Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis shows that the overall global antibacterial market for the seven indications tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media is valued at $11,070m in 2009. The market is expected to witness a growth at a CAGR of 1.5% for the forecast period and will reach $12,160m by 2016. Patent expiries of leading antbacterial, weak pipelines, increase in prevalence and prescription populations and easy availability of generic products are the main reason for growth in antbacterial market. The top pharmaceutical companies in antibacterial market companies Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCareAG, Johnson & Johnson, Daiichi-Sankyo and Teva pharmaceuticals. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions.

Scope

The scope of this report includes -
- Data and analysis on the global antibacterial market.
- Annualized market data for the antibacterial market from 2001 to 2009, with forecasts to 2016.
- Market data on the therapeutic landscape which covers tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global anticonvulsant market which includes companies such as Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCare AG, Johnson & Johnson, Daiichi-Sankyo and Teva.
- Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global antibacterial market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the regions antibacterial market.
- Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

  
Source:
Document ID
GBIHC067MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents312
  List of Tables83
  List of Figures114
Anti-Bacterials Market to 2016 Introduction151
  GBI Research Report Guidance151
Anti-Bacterials Market to 2016 Overview1610
  Bacterial Classification161
    Antimicrobial Spectrum161
    Bacterial Resistance161
    Cephalosporin Antibiotic161
      First Generation171
      Second Generation171
      Third Generation181
      Fourth Generation181
      Fifth Generation181
    Penicillin Antibiotic181
      Natural Penicillins191
      Penicillinase-Resistant Penicillins191
      Aminopenicillins191
      Extended Spectrum Penicillins191
    Quinolones Antibiotic201
      First Generation201
      Second Generation201
      Third generation201
      Fourth generation201
    Macrolide Antibiotic201
  Antibacterials Market Size211
    Antibacterial Market Size by Geography221
    Antibacterial Market Size by indication231
  Drivers and Barriers for the Antibacterial Market241
    Drivers for Antibacterial Market241
      Increase in the use of antibiotics241
      Drug Resistant Organisms241
      Depleting Environmental Conditions241
    Barriers for Antibacterial Market251
      Self-limiting Nature of the Disease251
      Increasing Antimicrobial Resistance251
      Patent Expiry of Branded Products251
      Weak Pipelines251
Anti-Bacterials Market to 2016 Tuberculosis2632
  Overview261
    Microbiology261
    Diagnosis261
    Treatment261
    Prevention271
  Tuberculosis Drugs Market Size271
  Tuberculosis Drugs Market Forecast and CAGR285
  Drivers and Barriers for Tuberculosis Therapeutics Market331
    Drivers for the Tuberculosis Drugs Market331
      Increase in Aged Population Increases Tuberculosis Prevalence331
      Decrease in Duration of Therapy331
    Barriers to Tuberculosis Drugs341
      Poor Compliance Rates341
      Lower Case Detection Rates341
      Affordability341
      Availability341
  Product Profile of the Major Marketed Products in the Tuberculosis Market341
    Isoniazid (INH)341
      Overview341
      Pricing351
    Rifampin (RIF)351
      Overview351
      Pricing351
    Pyrazinamide (PZA)351
      Overview351
      Pricing351
    Ethambutol (EMB)361
      Overview361
      Pricing361
    Kanamycin361
      Overview361
      Pricing361
    Ofloxacin361
      Overview361
      Pricing361
    Ethionamide371
      Overview371
      Pricing371
  Global Tuberculosis Market: Pipeline Analysis371
    Overview371
    Research and Development Pipeline- Discovery381
    Research and Development Pipeline Preclinical381
      Ac2SGL Diacylated Sulfoglycolipid381
      AdAg85A Vaccine381
      ApoVax104-TB Vaccine391
      FAS20013391
      HBHA391
      HG85 A/B391
      HG856A391
      HG856-BCG391
      HG856-SeV391
      HVJ-Envelope/HSP65 DNA + IL-12 DNA401
      MTBVAC01401
      NasL3/AM85B401
      NasL3/HtkBCG (BCG adjuvant)401
      paBCG Vaccine401
      PMX-10072401
      r30401
      r32kDa BCG Protein411
      rBCG T+B rM. smegmatis T+B411
      rBCG(mbtB)30411
      SQ109 + TMC207411
      Streptomyces Live Vector411
      VecFlu411
    Research and Development Pipeline - Phase I421
      Ad5Ag85A421
      Ag85B-ESAT-6 + CAF01421
      Ag85B-ESAT-6 Vaccine421
      AZD5847421
      FP85A421
      FP85A + MVA85A421
      PNU-100480431
      rBCG30431
      SQ109431
      Vaccine for Tuberculosis431
      VPM1002431
    Research and Development Pipeline - Phase II431
      Moxifloxacin + Rifapentine, Avelox + Priftin, Rifapentine + Moxifloxacin + Pyrazinamide + Isoniazid431
      AERAS-405, Crucell Ad35, Adenovirus 35, Crucell Ad35/AERAS-402431
      GSK M72441
      Interferon Gamma441
      Levofloxacin441
      Linezolid441
      LL 3858, Sudoterb, INH analogue, LL3858441
      Lopinavir + Ritonavir + NRTIs + Rifampicin441
      Metronidazole + Antituberculous Chemotherapy, Metronidazole441
      Moxifloxacin451
      Mtb72F/AS02, Mtb72F/AS02A TB vaccine451
      MVA85A, Recombinant modified vaccinia virus ankara 85A, MVA 85A451
      OPC-67683451
      PA-824451
      PA-824 + Pyrazinamide + Moxifloxacin451
      PA-824 + Pyrzinamide451
      Raltegravir + Tenofovir + Lamivudine461
      Recombinant Tuberculosis Vaccine461
      Rifabutin + Efavirenz461
      Rifabutin + Lopinavir/Ritonavir461
      Rifabutin + Nevirapine461
      Rifampicin461
      Rifapentine461
      Rifapentine471
      Ritonavir + Indinavir + Rifampicin, IDV/r + Rifampicin471
      RUTI471
      RUTI + Isoniazid471
      SQ109, SQ 109471
      SQ109 + Rifampicin, SQ109 + RIF471
      TMC 207, R207910, Bedaquiline, TMC207481
      TMC207 + Pyrazinamide, Bedaquiline + Pyrazinamide481
      V-5 Immunitor Vaccine + Anti-Tuberculosis Drugs, V-5 Immunitor Vaccine + ATT481
      Zyvox, Linezolid481
    Research and Development Pipeline - Phase III481
      Abacavir + Lamivudine + Zidovudine481
      Cholecalciferol491
      Didanosine + Lamivudine + Nevirapine + 2EHRZ3/4RH3491
      Efavirenz + Stavudine + Lamivudine491
      Immuvac491
      Isoniazid + Cotrimoxazole501
      Isoniazid + Ethambutol501
      Isoniazid + Rifampin501
      Isoniazid + Rifapentine501
      Mycobacterium vaccine501
      Nevirapine + Rifampicin + Ethambutol + Isoniazid + Pyrazinamid501
      Prednisone511
      RNTCP Category I Regimen511
      Tenofovir + Emtricitabine + Efavirenz511
  Global Tuberculosis Market: Strategic Consolidations521
    Overview521
    Merger and Acquisition Deals521
      Deals by Geography521
      Deals by Deal Type531
      Deals by Year531
      Deals by Value ($m)541
    Research and Development Licensing Agreements551
      Deals by Geography551
      Deals by Value551
      Deals by Year561
    Co-Developments561
      Co-Developments by Geography561
      Co-Developments by Year571
Anti-Bacterials Market to 2016 Pneumonia5828
  Overview581
    Microbiology581
    Diagnosis581
      Radiography581
      Laboratory Tests581
    Treatment591
    Prevention601
  Pneumonia Drugs Market Size601
  Pneumonia Drugs Market Forecast and CAGR619
  Drivers and Barriers to Pneumonia Therapeutics Market701
    Drivers to Pneumonia Drugs market701
      Increase in Diseased Population701
      Multi-Drug Resistant Organisms701
      Hospital Acquired Pneumonia701
    Barriers to Pneumonia Drugs market711
      Cost of Therapy711
      Weak Pipeline Reduces Market Potential711
  Product Profile of the Major Marketed Products in the Pneumonia Market711
    Zyvox (linezolid)711
      Overview711
    Zosyn (piperacillin and tazobactum)711
      Overview711
    Levaquin (Levofloxacin)721
      Overview721
    Avelox (moxifloxacin)721
      Overview721
    Omnicef (cefnidir)721
      Overview721
    Tygacil (tigecycline)721
      Overview721
    Doribax (doripenem)731
      Overview731
  Global Pneumonia Therapeutics Market: Pipeline Assessment731
    Overview731
    Discovery731
      Nasal Pneumococcal Vaccine731
      Mimopath Based Pneumococcal Vaccine731
    Pre-Clinical741
      ACE720741
      Aerucin741
      BL-2060741
      LipoNeu741
      PAC-G31P741
      Panaecin741
      Vansolin741
      Zysolin751
    Phase I751
      Chlorhexidine751
      GSK1322322751
      GSK2189241A751
      NKTR-063751
      Streptococcus Pneumoniae Vaccine751
      BC-3781751
      Torezolid751
      AZD9742761
    Phase II761
      IC43761
      KBPA101761
      Nemonoxacin761
      NXL103761
      Radezolid761
      Solithromycin761
      Amikacin Inhale771
      JNJ-32729463771
      GSK2189242A771
      7 Valent Pneumococcal Conjugate Vaccine (7vPCV)771
      PB-101771
    Phase III771
      Chlorhexidine771
      Prednisone771

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market" Feb 10, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Anti-Bacterials-Market-to-2016-Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market-2115-161>
  
APA:
GBI Research Reports. (2011). Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market Feb 10, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Anti-Bacterials-Market-to-2016-Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market-2115-161>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.